Pharming Group N.V. is a limited liability public company. Pharming Group N.V. is the ultimate parent company of Pharming Group. A list of our significant subsidiaries at December 31, 2022 is provided in the table below:
Company profile
Ticker
PHAR, PHGUF
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Latest filings (excl ownership)
6-K
Current report (foreign)
24 Apr 24
6-K
Current report (foreign)
8 Apr 24
6-K
Current report (foreign)
4 Apr 24
20-F
2023 FY
Annual report (foreign)
4 Apr 24
6-K
Current report (foreign)
14 Mar 24
6-K
Current report (foreign)
8 Jan 24
6-K
Current report (foreign)
15 Dec 23
6-K
Current report (foreign)
13 Nov 23
6-K
Current report (foreign)
26 Oct 23
6-K
Current report (foreign)
25 Sep 23
Latest ownership filings
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
News
Reported Earlier, Pharming Announces Completion of Enrollment in Pediatric Clinical Trial of Leniolisib
8 Apr 24
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target
14 Mar 24
Earnings Scheduled For March 14, 2024
14 Mar 24
Pharming Group Expects 2024 Total Revenue Of $280M-$295M
14 Mar 24
Pharming Q4 EPS $0.00 Up From $(0.02) YoY, Sales $81.20M Up From $54.62M YoY
14 Mar 24
Press releases
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
24 Apr 24
Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
8 Apr 24
Pharming Group to participate in April investor conferences
3 Apr 24
Pharming Group reports fourth quarter and full year 2023 financial results
14 Mar 24
Pharming Group to report fourth quarter and full year 2023 financial results on March 14
29 Feb 24